AstraZeneca and Idoven launch CONCERTO to advance early amyloidosis diagnosis. Read more here.

Collaborative research

At Idoven, we are at the forefront of global research, collaborating in international consortia and pioneering transformative scientific studies.

Explore our consortia
Get our Clinical Evidence

Amyloidosis Early Diagnosis based on AI for ECG Analysis

In partnership with AstraZeneca, CONCERTO aims to improve the early diagnosis of amyloidosis using AI-powered ECG analysis.

Cardiac amyloidosis is a rare and often underdiagnosed condition caused by abnormal protein deposits in the heart. Its symptoms frequently mimic those of more common diseases, leading to delays in diagnosis—sometimes by several years.

Through our Willem™ ECG platform, we are developing an AI model to detect subtle patterns that may signal early signs of amyloidosis—often missed even by experienced cardiologists. The goal: help clinicians diagnose earlier and connect patients with the care they need sooner.
Amyloidosis
2024-2027
Partners
Professionals
“
Many patients go through a long journey involving various medical consultations before receiving a definitive diagnosis. In some cases, it can take up to four years”
Quote from Dr. Pablo García-Pavía, Head of the Inherited Cardiac Diseases Unit at Puerta de Hierro Hospital, researcher at the National Center for Cardiovascular Research (CNIC) and CIBERCV, and Project Coordinator.
Partners
Professionals

Augmenting Heart Failure Detection in Primary Care with AI ECG Platform

The FAITHFUL Consortium, powered by WillemTM, Idoven's AI platform, aims to redefine heart failure detection in Primary Care, enhancing early detection to improve patient prognosis and anticipate a 40% reduction in hospitalizations, leading to significant healthcare cost savings.

Backed by €1.7 million from EIT Health Spain, an EU agency, and led by Idoven with support from AstraZeneca, this project involves the collaboration of 14 leading international institutions.
Heart Failure
2024-2025
Partners
Professionals

Building AI-based ECG analysis solution for early and accurate heart attack diagnosis

The ASSIST Consortium, powered by WillemTM, Idoven's AI platform, aims to swiftly and accurately diagnose suspected heart attacks in emergency units. This initiative focuses on reducing mortality, optimizing healthcare efficiency, and improving overall patient care.

Backed by €1.5 million from EIT Health Spain, an EU agency, and led by Idoven, this project involves the collaboration of 14 leading international institutions.
Heart attacks
2023-2025

The world's first machine learning platform for atrial cardiomyopathy diagnosis

The MAESTRIA Consortium aims to develop the first diagnostic digital platform for atrial cardiomyopathy, enhancing care management and identifying novel therapeutic targets for personalized medicine in cases of atrial fibrillation (AF) and stroke.

Funded with a €14 million grant from the Horizon 2020 European Commission, it unites Oxford University, Massachusetts General Hospital, and 15 other top-tier research institutions.
Atrial Fibrillation & Stroke
2021-2025
Partners
Professionals
Discover more

AI ECG Analysis for High-Risk Cardiac Patients

Explore WILLEM, Idoven's multicenter study validating our AI-powered ECG platform for early diagnosis and prediction of cardiac abnormalities in patients admitted to cardiovascular units.

Collaborating with hospitals in Spain and the Netherlands, our study aims to enhance automatic classification and prediction of cardiac issues, potentially preventing harmful treatments and lowering the risk of severe events.
Multiple cardiac diseases
2023-2025
Partners
Professionals
Discover more

Building a Multinational Data Platform and AI Solutions for Chronic Disease Management

The ARISTOTELES Consortium aims to develop trustworthy AI tools to predict the risk and progression of chronic diseases, enhancing patient care and management, with an initial focus on tackling the complexities of atrial fibrillation.

Funded with a €6 million grant from Horizon Europe 2022, the consortium is coordinated by Professors Giuseppe Boriani (University of Modena) and Gregory Y.H. Lip (University of Liverpool), Medical Advisor of Idoven, and includes 18 partners from 10 European countries.
Chronic Diseases
Atrial Fibrillation
Partners
Professionals
Discover more

Download the Clinical Evidence Behind Our Technology

Get our Clinical Evidence
Iker Casillas, Idoven investor & ambassador

Idoven main Consortiums and clinical studies

CONCERTO

2024-2027
Spain, Italy, France, Netherlands
To improve early diagnosis of cardiac amyloidosis—a rare and often underdiagnosed disease—through AI ECG analysis using Willem™, in partnership with AstraZeneca.
Amyloidosis
4.900+ participants

FAITHFUL

2024-2025
Spain, France, Sweden, Estonia
To redefine heart failure detection in Primary Care by integrating WillemTM, Idoven’s AI cardiology platform, into clinical practice. Funded by EIT Health with €1.7M.
Heart Failure
2.545 Patients

ASSIST

2023-2025
Spain, Netherlands, America 
To swiftly and accurately diagnose suspected heart attacks in emergency units using WillemTM, Idoven's AI-powered ECG analysis platform. Funded by EIT Health.
Heart attacks
10.340 Participants

WILLEM

2023-2025
Spain, Netherlands, Sweden, Switzerland
To validate the use of AI software to analyse EGM and ECG to identify cardiac patterns at a cardiologist-level.
Multiple Cardiac Diseases
40.000 Participants

ARISTOTELES

2023-2027
Italy, UK, Spain, Belgium, Norway, Others
To develop trustworthy AI tools to predict the risk of chronic diseases and their progression. Funded by Horizon Europe Health 2022 with €6M.
Chronic diseases
1.200 Patients

MAESTRIA

2021-2025
Spain, Netherlands, Switzerland
To develop the world's first machine learning platform for atrial cardiomyopathy diagnosis, aiming to enhance care management, and identify novel therapeutic targets for personalized medicine in atrial fibrillation and stroke cases.
Atrial Fibrillation
660 Participants

REDO-FIRM

2016-2020
US, Belgium, Netherlands, Germany
To evaluate the safety and effectiveness of FIRM-guided procedures in conventional "redo" RF ablation for atrial fibrillation, partnering with Abbott.
Atrial Fibrillation
269 Participants

UMBRELLA

2011-2017
Spain
To assess the prediction of paroxysmal to persistent atrial fibrillation, conducted across 51 centers for ICD/CRT-D and 2 centers for pacemakers, partnering with Medtronic.
Atrial Fibrillation
4.648 Participants

Our science

We are working with world-class research centres in cardiovascular research. Our R&D demonstrate scientific advances in cardiology and machine learning, published in high-impact factor journals such as Nature, Heart, European Heart Journal, Circulation and Europace.

Our publications
Product
Our technology
For MedTech
For Life Sciences
Preventative Screening Programs
Pre-Initiation ECG Testing (Pharma)
Our company
About usOur teamJobsBlogNewsRegulatoryIker CasillasPau Gasol
Science & impact
Collaborative researchPublicationsImpact#Donateyour
heartbeats
Privacy policyQuality, Security & AI policyCookie policyLegal terms & conditionsUser guidesAnti-bribery Policy
GDPR compliant and
certified for ISO 27001

Contact

Revolutionize cardiovascular care with Idoven. Discuss the possibilities with us.
Reach out and start something great
No job match? Apply for future opening
Thank you!
We will get back to you within 5 days, please check your spam folder
Back to Idoven
Oops! Something went wrong while submitting the form.
Thank you!
We will get back to you within 5 days, please check your spam folder
Back to Idoven
Oops! Something went wrong while submitting the form.

Download our Clinical Evidence